FDA Approval of Jemperli for Endometrial Cancer Treatment
The FDA has approved a new immunotherapy drug called Jemperli for certain adult patients with endometrial cancer. This is the third FDA approval this year for immunotherapy in endometrial cancer, showing improved outcomes for patients.
Key Points
- Jemperli is an immunotherapy-based drug made by British pharmaceutical company GSK
- Immunotherapy in combination with chemotherapy has shown better results with manageable toxicity profiles
- The addition of immunotherapy to chemotherapy has improved survival outcomes without a negative impact on quality of life
Pros
- Improved progression-free survival and overall survival for patients with endometrial cancer
- Game-changing results with three FDA approvals for immunotherapy in endometrial cancer in a short period of time
Cons
- Common side effects of immunotherapy drugs include gastrointestinal, endocrine, and dermatologic toxicities